Mark Rothera, Silence Therapeutics CEO

With first hu­man da­ta, long-strug­gling Si­lence Ther­a­peu­tics leaps in­to next big car­dio­vas­cu­lar race

Drug com­pa­nies have spent the last 40-plus years search­ing for in­creas­ing­ly high-tech ways of low­er­ing bad cho­les­terol in hopes of curb­ing heart dis­ease, still the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.